Clinical Trial Update: A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing once-daily versus twice-daily empagliflozin (BI 10773) added to metformin in type 2 diabetes reported efficacy and safety results, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2015-07-23